Article

The impact of mutational clonality in predicting the response to immune checkpoint inhibitors in advanced urothelial cancer

2023-04-13

Abstract excerpt

Immune checkpoint inhibitors (ICI) have revolutionized cancer treatment and can result in complete remissions even at advanced stages of the disease. However, only a small fraction of patients respond to the treatment. To better understand which factors drive clinical benefit, we have generated whole exome and RNA sequencing data from 27 advanced urothelial carcinoma patients treated with anti-PD-(L)1 monoclonal a...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: f9352561-e8ea-5f7a-ac32-a98ca791eb7d
DOI: 10.21203/rs.3.rs-2782434/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

The impact of mutational clonality in predicting the response to immune checkpoint inhibitors in advanced urothelial cancerDOI 10.21203/rs.3.rs-2782434/v1Read

The impact of mutational clonality in predicting the response to immune checkpoint inhibitors in advanced urothelial cancer.Semantic proximity Read

Contribution of systemic and somatic factors to clinical response and resistance in urothelial cancer: an exploratory multi-omic analysisSemantic proximity Read

Tumor Mutational Burden as a Predictive Biomarker for Response to Immune Checkpoint Inhibitors: A Review of Current EvidenceSemantic proximity Read

Is tumor mutational burden predictive of response to immunotherapy?Semantic proximity Read

Beyond Tumor PD-L1: Emerging Genomic Biomarkers for Checkpoint Inhibitor ImmunotherapySemantic proximity Read

PD-L1 expression and tumor mutational burden are independent biomarkers in most cancersSemantic proximity Read

Tumor mutational burden related classifier is predictive of response to PD-L1 blockade in locally advanced and metastatic urothelial carcinoma.Semantic proximity Read

Whole-genome sequencing uncovers the genomic determinants of therapeutic resistance to immune checkpoint blockadeSemantic proximity Read

Predicting immunotherapy response in advanced bladder cancer: a meta-analysis of six independent cohortsSemantic proximity Read

Induced B-Cell Receptor Diversity Predicts PD-1 Blockade Immunotherapy ResponseSemantic proximity Read

Meta-analysis of tumor- and T cell-intrinsic mechanisms of sensitization to checkpoint inhibition.Semantic proximity Read

Immune Determinants of the Association between Tumor Mutational Burden and Immunotherapy Response across Cancer Types.Semantic proximity Read